- Aids to daily living
- Ambulatory Products
- Bath Safety
- Beds Acc
- Core Wound Care
- Diabetic
- Enteral Nutrition Feed
- Home Diagnostics
- Impotence
- Incontinence
- Infusion IV Supplies
- Lift Chairs Geri Chairs
- Lympedema Pumps Acc
- Lymphedema Pumps Acc
- Medications OTC
- Miscellaneous
- Needles Syringes
- Orthopedics
- Ostomy
- Pain Management
- Patient Lifts Acc
- Personal Protect Gloves
- Prof Use and Diagnostics
- Respiratory
- Scooters Acc
- Seating Cushions
- Skin Care
- Socks Stockings
- Specialty Med Equip Acc
- Specialty Wound Care
- Tracheostomy Care
- Urol Collection Devices
- Urological Catheters
- Vitamins Oral Meds
- Wheelchairs Acc
- Womens Infant Products
- Womens Infant Products
- Broadband
Featured Products
Office Address:
Diabetic Corner
13157 March way
Corona California 92879
Phone Numbers:
Office:1951-549-9114
Fax:1951-898-2604
E-mail: Contact Form
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Description:
Inflammatory Lung Injury Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P(1 µM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50% reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction. Medical Supply. Suction Pumps-Accessories, Aspirators, Suction Catheters, Pumps, Humidification.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
